Algorithm for antithrombotic therapy in patients with ischemic stroke after thrombolysis
https://doi.org/10.21518/2079-701X-2014-7-39-42
Abstract
Systemic thrombolytic therapy in patients with ischemic stroke is an effective treatment for a certain category of patients during the first 4.5 hours after the symptom onset. However, according to the treatment protocol, administration of any antithrombotic drugs during the first days after thrombolysis is contraindicated. At the same time, 24 hours after thrombolysis the need remains for the intake of antithrombotic agents for the purpose of secondary prophylaxis of stroke. We described our own experience in the use of antiplatalets in patients with ischemic stroke after thrombolytic therapy.
About the Authors
MA Domashenko
Neurology Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
MY Maksimova
Neurology Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
MM Tanashyan
Neurology Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008-2009. URL: http://www.eso-stroke. org/recommendations.
2. Jauch E et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2013, 44: published online January 31, 2013.
3. Ahmed N et al. Implementation and outcome of thrombolysis with alteplase 3-4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology, 2010, 9: 866-74.
4. Суслина З.А., Высоцкая В.Г Антиагрегационное действие и клинический эффект малых доз аспирина при лечении больных с цереброваскулярной патологией на фоне артериальной гипертензии. Клиническая медицина, 1983, 9: 51-59.
5. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet, 1997, 349: 1569-1581.
6. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet, 1997, 349: 1641-1649.
7. Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинической и экспериментальной неврологии, 2007, 1: 17-22.
8. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology, 2002, 59: 862-67.
9. Rothwell P.M. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet, 2007, 370: 1432-42.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333: 1581-7.
11. Lees K et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010, 375: 1695-703.
12. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 1962, 194: 927-9.
13. O'Brien J. A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J Clin Pathol., 1964, 17: 275-81.
Review
For citations:
Domashenko M, Maksimova M, Tanashyan M. Algorithm for antithrombotic therapy in patients with ischemic stroke after thrombolysis. Meditsinskiy sovet = Medical Council. 2014;(7):39-42. (In Russ.) https://doi.org/10.21518/2079-701X-2014-7-39-42
Views:
586
Email this article 